New pump insulin could speed up blood sugar control for type 1 diabetes

NCT ID NCT06809621

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study tested a new fast-acting insulin called NNC0471-0119 in 43 adults with type 1 diabetes who use an insulin pump. The goal was to see how quickly the insulin enters the bloodstream, how long it works, and how safe it is compared to a standard insulin (insulin aspart). Each participant received both insulins at separate visits. The study lasted about 1-3 months and measured blood sugar-lowering effects and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0471-0119 (a fast-acting insulin)
What this could lead to: If successful, this could lead to a faster-acting insulin for insulin pumps, helping people with type 1 diabetes manage blood sugar more effectively after meals.
What could go wrong: This is a small, early-phase study (Phase 1) focused on safety and how the drug works in the body. It may not show better results than existing insulins, and further larger trials are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.